Onchocerciasis Clinical Trial
Official title:
Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis
This DOLF study will investigate the safety and effectiveness of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and eyes.
This study will provide preliminary data on the safety of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with IVM to clear or greatly reduce microfilariae from the skin and eyes. Widespread use of IDA following IVM pretreatment (I/IDA) has the potential to greatly accelerate elimination of lymphatic filariasis (LF) in African countries that are co-endemic for LF and onchocerciasis. study later. This study will also assess the efficacy of IDA for killing and sterilizing adult filarial worms. An improved macrofilaricidal treatment would be a major advance for the global program to eliminate onchocerciasis. Since the safety and efficacy objectives are both very important, we have included dual primary objectives for the study. Primary objectives: - Safety: To compare rates and types of severe adverse events (grade 3 or higher) that occur within 7 days following 1 day or 3 days of treatment with triple drug treatment ("IDA" = diethylcarbamazine (DEC) with ivermectin (IVM) and albendazole (ALB)) with the comparator regimen of 1 day of treatment with ivermectin and albendazole (IA) in persons with active Onchocerca volvulus infections after pretreatment with ivermectin alone. - Efficacy: To compare the effect of three treatment regimens (1 day of IDA, 3 days of IDA, or IA) for killing or sterilizing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. This is an open label, randomized clinical trial. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00300768 -
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
|
Phase 2 | |
Not yet recruiting |
NCT04035174 -
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
|
N/A | |
Recruiting |
NCT03653975 -
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
|
||
Completed |
NCT03052998 -
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
|
Phase 4 | |
Active, not recruiting |
NCT04311671 -
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
|
Phase 3 | |
Active, not recruiting |
NCT03876262 -
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
|
Phase 3 | |
Terminated |
NCT04913610 -
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
|
Phase 2 | |
Completed |
NCT03962062 -
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
|
Phase 1 | |
Completed |
NCT01905436 -
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
|
||
Recruiting |
NCT00001230 -
Host Response to Infection and Treatment in Filarial Diseases
|
||
Completed |
NCT05750043 -
Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
|
||
Completed |
NCT05749653 -
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
|
N/A | |
Completed |
NCT02078024 -
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
|
Phase 3 | |
Completed |
NCT00127504 -
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
|
Phase 2 | |
Completed |
NCT03131401 -
Prevalence of LF Infection in Districts Not Included in LF Control Activities
|
||
Completed |
NCT02032043 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
|
||
Terminated |
NCT05084560 -
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
|
Phase 1 | |
Completed |
NCT03517462 -
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
|
N/A | |
Active, not recruiting |
NCT05180461 -
Emodepside Phase II Trial for Treatment of Onchocerciasis
|
Phase 2 | |
Enrolling by invitation |
NCT06070116 -
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
|
Phase 2 |